Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyFRA:8C5 +2.51%49 ROC (Joel Greenblatt) % is -11,478.00% as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 49/100 and a GF Value™ of €0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,323 Biotechnology companies, Coherus Oncology ranks worse than 90.4% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Coherus Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11,478.00%.
The historical rank and industry rank for Coherus Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:8C5'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9934.67 Med: -835.94 Max: 300.26
Current: -9934.67
During the past 13 years, Coherus Oncology's highest ROC (Joel Greenblatt) % was 300.26%. The lowest was -9934.67%. And the median was -835.94%.
FRA:8C5's ROC (Joel Greenblatt) % is ranked worse than 90.4% of 1323
companies
in the Biotechnology industry
Industry Median: -297.52
vs FRA:8C5: -9934.67
Coherus Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Coherus Oncology ROC (Joel Greenblatt) % Related Terms
Coherus Oncology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Coherus Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -11,478.00% mean?
Coherus Oncology (FRA:8C5) has a ROC (Joel Greenblatt) % of -11,478.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #1196 out of 1323 companies in the Biotechnology industry, placing it in the top 90.4%.
Is Coherus Oncology's ROC (Joel Greenblatt) % too high?
Coherus Oncology's current ROC (Joel Greenblatt) % is -11,478.00%. Based on the distribution chart, Coherus Oncology ranks #1196 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's ROC (Joel Greenblatt) % compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1196 out of 1323 companies for ROC (Joel Greenblatt) %. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current ROC (Joel Greenblatt) % is -11,478.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.27 — trading 83.5% above its estimated fair value. The current ROC (Joel Greenblatt) % is -11,478.00%. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current ROC (Joel Greenblatt) % is -11,478.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.27 is trading 83.5% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
ROC (Joel Greenblatt) %: -11,478.00%
GF Value™: €0.69 vs. price of €1.27 (83.5% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
